Anzeige
Mehr »
Login
Montag, 06.05.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
+56,25% in 5 Tagen: Genialer Schachzug - diese Übernahme verändert alles
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
121 Leser
Artikel bewerten:
(0)

Professor Brian Wilson Receives IPA Excellence Award In Photodiagnostic Research

COIMBRA, Portugal, July 10, 2017 /PRNewswire/ -- At the 16th International Photodynamic Association (IPA) World Congress in Coimbra, Professor Brian Wilson was the recipient of the 2017 EXCELLENCE AWARD IN PHOTODIAGNOSTIC RESEARCH.

Professor Brian Wilson

Dr. Brian Wilson is Professor of Medical Biophysics at Princess Margaret Cancer Centre/University Health Network, Universityof Toronto, Canada.He is a well-known expert and leader in the field of PDT and Photodiagnostics, internationally recognized for his pioneering research into various optic tools that can be used for minimally-invasive cancer treatment, and early diagnosis and optically-guided cancer therapeutics. He holds several awards in biomedical optics (Mark Award, NIH Translational Research Award, Michael S. Feld Award and Britton Chance Award) and in cancer research (Robert L. Noble Prize).

In 1981, Dr. Wilson initiated translational research and collaborative clinical trials of photodynamic therapy for brain, prostate and gastrointestinal cancers. Dr. Wilson leads a world-renowned R&D program in optics-based biomedical applications, with a primary translational/clinical focus. He has driven the development of fluorescence and other endoscopic imaging techniques - particularly in Barrett's esophagus and colon cancer - and more recently has developed optical imaging to guide surgery that is being evaluated in clinical trials for head and neck, prostate and brain cancers. In the last few years, his research has expanded to include development of photonic nanoparticles in cancer treatment, diagnosis and research. Dr. Wilson has published over 350 peer-reviewed papers in basic, translational and clinical research. With several international Visiting Appointments (Harvard, USA; Saõ Paulo, Brazil; Fujian, China; Western Australia), Dr. Wilson is involved in many national and international collaborations.Dr. Wilson has trained more than 50 graduate students, post-doctoral and clinical fellows, many of whom remain in biomedical optics, cancer research and practice worldwide. He also has worked with many companies nationally and internationally in translating optical technologies into clinical practice.

The Coimbra World Congress was the 16thconference held by the International Photodynamic Association, marking 32 years of this global meeting. The IPA World Congresses, held every two years, are the leading PDT meetings bringing together members of the global photodynamic community in order to advance scientific and clinical research relating to photodiagnosis and photodynamic therapies. The next IPA World Congress is to be hosted in Boston, USA and will be led by Dr. Tayyaba Hasan, Professor of Dermatology at the Wellman Center for Photomedicine, Harvard Medical School (HMS) and a Professor of Health Sciences and Technology (Harvard-MIT).

About Photodynamic Therapy (PDT)

Photodynamic Therapy (PDT) is a combination therapy involving light activated photosensitizers to diagnose and treat various types of cancers and pre-cancers, macular degeneration and multidrug resistant biofilm infections involving bacteria, viruses and fungi.

For more information, please contact: ipasecretary@internationalphotodynamic.com

Photo - http://mma.prnewswire.com/media/534082/brian_wilson1.jpg

Lithium vs. Palladium - Zwei Rohstoff-Chancen traden
In diesem kostenfreien PDF-Report zeigt Experte Carsten Stork interessante Hintergründe zu den beiden Rohstoffen inkl. . Zudem gibt er Ihnen konkrete Produkte zum Nachhandeln an die Hand, inkl. WKNs.
Hier klicken
© 2017 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.